Take this short true or false quiz about treating related symptoms.
Important Safety Information  |  Prescribing Information
NovoSeven® RT Coagulation Factor VIIa (Recombinant) logo.
NovoSeven® RT is used to treat bleeding episodes in people with hemophilia A or B with inhibitors, congenital Factor VII deficiency, Glanzmann’s thrombasthenia with resistance to platelets, and acquired hemophilia.
You’re the expert on life with Glanzmann’s thrombasthenia.
This short quiz may offer new insight on treating symptoms related to Glanzmann’s thrombasthenia (GT). Start the quiz below.
If I experience a nosebleed, I can infuse at home.
 True 
 False 
Woman looking away
 
Scroll to learn more about NovoSeven® RT.
Selected Important Safety Information
What is the most important information I should know about NovoSeven® RT?
NovoSeven® RT may cause serious side effects, including:
• Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported
• Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function
• Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT
Please click here or scroll below for additional Important Safety Information.
Features of NovoSeven® RT.
If platelets don't work for you, NovoSeven® RT
may be right for treating your GT-related bleeds.
Quick to mix with a prefilled syringe
Fast and effective bleed
control
for bleeding episodes and surgery
Established safety profile
that comes from years of experience
What is NovoSeven® RT?
NovoSeven® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for:
• Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with a decreased or absent response to platelet transfusions
• Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia
Important Safety Information (cont’d)
• You should not use NovoSeven® RT if you have ever had allergic (hypersensitivity) reactions, including severe, whole body reactions (anaphylaxis) to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. Signs of allergic reaction include shortness of breath, rash, itching (pruritus), redness of the skin (erythema), or fainting/dizziness
What should I tell my healthcare provider before using NovoSeven® RT?
• Tell your healthcare provider if you have any of the following, as these may increase your risk of blood clots:
 
◦ congenital hemophilia and are also receiving treatment with aPCCs (activated prothrombin complex concentrates)
◦ are an older patient particularly with acquired hemophilia and receiving other agents to stop bleeding
◦ history of heart or blood vessel diseases
• Tell your healthcare provider and pharmacist about all the medicines you take, including all prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies
What are the possible side effects of NovoSeven® RT?
• The most common and serious side effects are blood clots
• Tell your healthcare provider about any side effects that bother you or do not go away, and seek medical help right away if you have signs of a blood clot or allergic reaction
Please click here for Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
PLEASE DO NOT RESPOND TO THIS EMAIL. If you would like to contact us, please click here or call 1‑877‑744‑2579.
NovoSeven® is a registered trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2020 Novo Nordisk  All rights reserved.  US19NSVN00138  September 2020
Novo Nordisk logo.
Novo Nordisk logo.